Blueprint Medicines (BPMC) Short Interest Ratio & Short Volume $110.05 +6.10 (+5.87%) Closing price 04:00 PM EasternExtended Trading$112.25 +2.20 (+2.00%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Blueprint Medicines Short Interest DataBlueprint Medicines (BPMC) has a short interest of 5.10 million shares. This marks a 12.58% increase in short interest from the previous month. The short interest ratio (days to cover) is 7.9, indicating that it would take 7.9 days of the average trading volume of 989,443 shares to cover all short positions.Current Short Interest5,100,000 sharesPrevious Short Interest4,530,000 sharesChange Vs. Previous Month+12.58%Dollar Volume Sold Short$444.82 millionShort Interest Ratio7.9 Days to CoverLast Record DateDecember 31, 2024Outstanding Shares63,530,000 sharesPercentage of Shares Shorted8.03%Today's Trading Volume970,190 sharesAverage Trading Volume989,443 sharesToday's Volume Vs. Average98% Short Selling Blueprint Medicines? Sign up to receive the latest short interest report for Blueprint Medicines and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartBPMC Short Interest Over TimeBPMC Days to Cover Over TimeBPMC Percentage of Float Shorted Over Time Blueprint Medicines Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/31/20245,100,000 shares $444.82 million +12.6%N/A7.9 $87.22 12/15/20244,530,000 shares $422.15 million +8.1%N/A7.2 $93.19 11/30/20244,190,000 shares $403.83 million +7.2%N/A6.7 $96.38 11/15/20243,910,000 shares $346.78 million -5.3%N/A6.1 $88.69 10/31/20244,130,000 shares $361.42 million +14.1%N/A6.8 $87.51 10/15/20243,620,000 shares $322.83 million +2.6%N/A5.5 $89.18 Get the Latest News and Ratings for BPMC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. 9/30/20243,530,000 shares $326.53 million -3.8%N/A5.3 $92.50 9/15/20243,670,000 shares $326.26 million -7.3%N/A5.3 $88.90 8/31/20243,960,000 shares $378.34 million -2.2%N/A5.8 $95.54 8/15/20244,050,000 shares $386.86 million -8.2%N/A6.1 $95.52 7/31/20244,410,000 shares $477.60 million -7.9%N/A6.6 $108.30 7/15/20244,790,000 shares $572.55 million +5.0%N/A7.6 $119.53 6/30/20244,560,000 shares $491.48 million +3.6%N/A7.4 $107.78 6/15/20244,400,000 shares $464.42 million -0.9%N/A7.2 $105.55 5/31/20244,440,000 shares $468.69 million -1.8%N/A6.8 $105.56 5/15/20244,520,000 shares $482.69 million -0.4%N/A6.2 $106.79 4/30/20244,540,000 shares $414.68 million +6.8%N/A5.5 $91.34 4/15/20244,250,000 shares $362.02 million -2.8%N/A5.4 $85.18 3/31/20244,370,000 shares $414.54 million -15.2%N/A5.6 $94.86 3/15/20245,150,000 shares $466.08 million +0.2%N/A6.3 $90.50 2/29/20245,140,000 shares $480.69 million +11.0%N/A5.8 $93.52 2/15/20244,630,000 shares $405.45 million +0.7%N/A5.4 $87.57 1/31/20244,600,000 shares $365.84 million +5.3%N/A5.9 $79.53 1/15/20244,370,000 shares $362.40 million +9.0%N/A5 $82.93 12/31/20234,010,000 shares $369.88 million -4.1%N/A4.6 $92.24 12/15/20234,180,000 shares $367.55 million -4.1%N/A5.1 $87.93 11/30/20234,360,000 shares $303.63 million +4.6%N/A6.2 $69.64 11/15/20234,170,000 shares $265.50 million -6.3%N/A6.6 $63.67 10/31/20234,450,000 shares $261.93 million +1.4%N/A7.4 $58.86 10/15/20234,390,000 shares $214.80 million -1.1%N/A7.2 $48.93 9/30/20234,440,000 shares $222.98 million +6.7%N/A7.4 $50.22 9/15/20234,160,000 shares $210.58 million +1.7%N/A6.8 $50.62 8/31/20234,090,000 shares $203.93 million +4.6%N/A6.2 $49.86 8/15/20233,910,000 shares $201.17 million +2.9%N/A5.4 $51.45 7/31/20233,800,000 shares $250.80 million +6.2%N/A5.2 $66.00 7/15/20233,580,000 shares $206.24 million -7.3%N/A5.6 $57.61 6/30/20233,860,000 shares $243.95 million -2.3%N/A6.2 $63.20 6/15/20233,950,000 shares $240.52 million +7.1%N/A6.6 $60.89 5/31/20233,690,000 shares $208.56 million +3.1%N/A6.3 $56.52 5/15/20233,580,000 shares $197.40 million -5.8%N/A6 $55.14 4/30/20233,800,000 shares $193.99 million -11.8%N/A6.4 $51.05 4/15/20234,310,000 shares $201.97 million +1.7%N/A7.7 $46.86 3/31/20234,240,000 shares $190.76 million -19.4%N/A7.4 $44.99 3/15/20235,260,000 shares $237.54 million -4.9%N/A9.3 $45.16 2/28/20235,530,000 shares $234.31 million +1.8%N/A9.6 $42.37 2/15/20235,430,000 shares $239.08 million +8.4%N/A10 $44.03 1/31/20235,010,000 shares $234.17 million +4.4%8.6%9.6 $46.74 1/15/20234,800,000 shares $229.68 million +3.7%8.2%7.7 $47.85 12/30/20224,630,000 shares $202.84 million +8.4%7.9%6.8 $43.81 12/15/20224,270,000 shares $192.62 million -0.5%7.3%6.2 $45.11 11/30/20224,290,000 shares $205.02 million +1.2%7.4%6.2 $47.79 11/15/20224,240,000 shares $184.99 million +15.9%7.3%5.9 $43.63 10/31/20223,660,000 shares $189.73 million -10.5%6.3%4.2 $51.84 10/15/20224,090,000 shares $212.60 million -6.2%7.1%4.8 $51.98 9/30/20224,360,000 shares $287.28 million -1.1%7.5%5.4 $65.89 9/15/20224,410,000 shares $320.12 million -20.1%7.6%5.2 $72.59 8/31/20225,520,000 shares $404.17 million +17.0%9.6%5.6 $73.22 8/15/20224,720,000 shares $330.16 million -10.4%8.2%4.9 $69.95 7/31/20225,270,000 shares $269.09 million +1.4%9.1%6.4 $51.06 7/15/20225,200,000 shares $278.46 million -10.0%9.0%6.6 $53.55 6/30/20225,780,000 shares $291.95 million +3.8%10.0%7.5 $50.51 6/15/20225,570,000 shares $267.19 million +17.0%9.7%7.3 $47.97 5/31/20224,760,000 shares $261.80 million +15.3%8.3%7.5 $55.00 5/15/20224,130,000 shares $226.94 million +14.1%7.2%6.2 $54.95 4/30/20223,620,000 shares $211.23 million +5.9%6.3%5.3 $58.35 4/15/20223,420,000 shares $232.63 million -2.3%6.0%5.1 $68.02 3/31/20223,500,000 shares $223.58 million +11.8%6.1%5 $63.88 3/15/20223,130,000 shares $183.29 million +3.6%5.5%4.9 $58.56 2/28/20223,020,000 shares $182.86 million -2.0%5.3%4.9 $60.55 2/15/20223,080,000 shares $256.29 million -2.5%5.4%5.4 $83.21 1/31/20223,160,000 shares $243.64 million +21.5%5.5%6.7 $77.10 1/15/20222,600,000 shares $202.80 million -3.0%4.5%5.6 $78.00 12/31/20212,680,000 shares $287.05 million +11.2%4.6%6.6 $107.11 12/15/20212,410,000 shares $251.15 million -8.7%4.2%6.6 $104.21 11/30/20212,640,000 shares $253.97 million +0.8%4.6%7.3 $96.20 11/15/20212,620,000 shares $301.72 million +10.1%4.5%7.2 $115.16 10/29/20212,380,000 shares $267.73 million -15.0%4.1%6.5 $112.49 10/15/20212,800,000 shares $280.42 million -3.8%4.9%7.7 $100.15 9/30/20212,910,000 shares $299.18 million -9.4%5.1%7.4 $102.81 9/15/20213,210,000 shares $332.97 million -3.9%5.6%7.1 $103.73 8/31/20213,340,000 shares $311.52 million -8.7%5.8%6.1 $93.27 8/13/20213,660,000 shares $345.94 million +2.0%6.3%6.4 $94.52 7/30/20213,590,000 shares $315.45 million +9.1%6.2%6.2 $87.87 7/15/20213,290,000 shares $267.41 million -7.1%5.7%6.1 $81.28 6/30/20213,540,000 shares $311.38 million +7.9%6.2%6.7 $87.96 6/15/20213,280,000 shares $276.41 million -8.9%5.7%7 $84.27 5/28/20213,600,000 shares $328.86 million +5.3%6.3%9.1 $91.35 5/14/20213,420,000 shares $317.38 million +2.4%N/A9.2 $92.80 4/30/20213,340,000 shares $330.23 million +2.5%N/A8.5 $98.87 4/15/20213,260,000 shares $315.76 million +4.2%N/A7.8 $96.86 3/31/20213,130,000 shares $291.94 million -0.3%N/A7.4 $93.27 3/15/20213,140,000 shares $337.11 million +4.7%N/A6.6 $107.36 2/26/20213,000,000 shares $288.27 million +4.9%N/A6.1 $96.09 2/12/20212,860,000 shares $286.89 million -0.7%N/A5.8 $100.31 1/29/20212,880,000 shares $280.02 million -5.3%N/A6 $97.23 1/15/20213,040,000 shares $311.63 million +10.6%N/A6.1 $102.51 12/31/20202,750,000 shares $316.25 million -11.3%N/A5.5 $115.00 12/15/20203,100,000 shares $363.66 million -4.9%N/A6.3 $117.31 11/30/20203,260,000 shares $349.67 million -5.5%N/A6.8 $107.26 11/15/20203,450,000 shares $347.48 million -6.8%N/A7.5 $100.72 10/30/20203,700,000 shares $395.31 million -15.5%N/A8.5 $106.84 10/15/20204,380,000 shares $434.98 million +4.0%N/A10.4 $99.31 9/30/20204,210,000 shares $390.27 million +3.7%N/A8.8 $92.70 9/15/20204,060,000 shares $296.38 million +9.1%N/A8.4 $73.00 8/31/20203,720,000 shares $288.04 million +2.5%N/A8.3 $77.43 8/14/20203,630,000 shares $268.47 million +0.8%N/A7.5 $73.96 7/31/20203,600,000 shares $263.45 million -12.6%N/A6.7 $73.18 7/15/20204,120,000 shares $329.48 million -1.9%N/A6.5 $79.97 6/30/20204,200,000 shares $321.51 million +4.7%N/A7.1 $76.55 6/15/20204,010,000 shares $292.85 million +9.9%N/A6.2 $73.03 5/29/20203,650,000 shares $237.76 million +4.0%N/A4.7 $65.14 5/15/20203,510,000 shares $223.17 million +10.7%N/A4.4 $63.58 4/30/20203,170,000 shares $186.49 million -14.1%N/A3.9 $58.83 4/15/20203,690,000 shares $237.38 million -4.7%N/A4.3 $64.33 3/31/20203,870,000 shares $273.57 million +26.4%N/A4.2 $70.69 3/13/20203,062,100 shares $202.71 million +4.9%7.3%4.3 $66.20 2/28/20202,920,000 shares $149.85 million +8.6%7.0%3.9 $51.32 2/14/20202,690,000 shares $155.51 million -22.0%N/A3.8 $57.81 1/31/20203,450,000 shares $198.58 million -6.5%N/A5.1 $57.56 BPMC Short Interest - Frequently Asked Questions What is Blueprint Medicines' current short interest? Short interest is the volume of Blueprint Medicines shares that have been sold short but have not yet been closed out or covered. As of December 31st, investors have sold 5,100,000 shares of BPMC short. Learn More on Blueprint Medicines' current short interest. What is a good short interest ratio for Blueprint Medicines? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BPMC shares currently have a short interest ratio of 8.0. Learn More on Blueprint Medicines's short interest ratio. Which institutional investors are shorting Blueprint Medicines? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Blueprint Medicines: JPMorgan Chase & Co., Jane Street Group LLC, Wolverine Trading LLC, Walleye Trading LLC, Walleye Capital LLC, PEAK6 Investments LLC, and BNP Paribas Financial Markets. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Blueprint Medicines' short interest increasing or decreasing? Blueprint Medicines saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 5,100,000 shares, an increase of 12.6% from the previous total of 4,530,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Blueprint Medicines' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Blueprint Medicines: Teva Pharmaceutical Industries Limited (2.39%), BeiGene, Ltd. (1.41%), Genmab A/S (0.22%), Viatris Inc. (2.96%), Intra-Cellular Therapies, Inc. (1.87%), Summit Therapeutics Inc. (2.70%), Moderna, Inc. (11.03%), Dr. Reddy's Laboratories Limited (1.57%), Catalent, Inc. (8.12%), Sarepta Therapeutics, Inc. (5.37%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.83 billion), Charter Communications, Inc. ($3.77 billion), Reddit, Inc. ($2.98 billion), The Kroger Co. ($2.97 billion), International Paper ($2.64 billion), SoFi Technologies, Inc. ($1.99 billion), Rivian Automotive, Inc. ($1.93 billion), Onsemi ($1.81 billion), SoundHound AI, Inc. ($1.59 billion), and Moderna, Inc. ($1.57 billion). View all of the most shorted stocks. What does it mean to sell short Blueprint Medicines stock? Short selling BPMC is an investing strategy that aims to generate trading profit from Blueprint Medicines as its price is falling. BPMC shares are trading up $6.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Blueprint Medicines? A short squeeze for Blueprint Medicines occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BPMC, which in turn drives the price of the stock up even further. How often is Blueprint Medicines' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BPMC, twice per month. The most recent reporting period available is December, 31 2024. More Short Interest Resources from MarketBeat Related Companies Teva Pharmaceutical Industries Short Interest Data BeiGene Short Interest Data Genmab A/S Short Interest Data Viatris Short Interest Data Intra-Cellular Therapies Short Interest Data Summit Therapeutics Short Interest Data Moderna Short Interest Data Dr. Reddy's Laboratories Short Interest Data Catalent Short Interest Data Sarepta Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BPMC) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
